| Date | Title | Description | |
|---|---|---|---|
| 24 Jun 2024 | On business and financial situation | ROVI publishes the press release in relation to information and guidance on its strategic plan for expansion and growth | Download |
| 08 May 2024 | On P&L | The Company releases the press release related to the first three months of 2024 financial results | Download |
| 08 May 2024 | On P&L | The Company releases the first three months 2024 financial results presentation | Download |
| 25 Apr 2024 | On business and financial situation | ROVI announces agreement to manufacture pre-filled syringes | Download |
| 27 Feb 2024 | On P&L | The Company releases the press release related to the full year 2023 financial results. | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 17 Dec 2021 | On business and financial situation | ROVI reports that the CHMP has issued a positive opinion on Okedi® for the treatment for schizophrenia | Download |
| 13 Dec 2021 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 6 December 2021 and 10 December 2021 | Download |
| 06 Dec 2021 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 29 November 2021 and 3 December 2021 | Download |
| 22 Nov 2021 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 15 November 2021 and 19 November 2021 | Download |
| 16 Nov 2021 | Liquidity and counterparty agreements | The Company informs of the termination of the Liquidity Agreement | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 26 Feb 2019 | Información sobre resultados | ROVI releases the presentation related to the full year 2018 results | Download |
| 26 Feb 2019 | Información sobre resultados | ROVI releases the press release related to the full year 2018 results | Download |
| 15 Feb 2019 | Others on business performance and financial information | ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French markets | Download |
| 09 Jan 2019 | Others on business performance and financial information | ROVI informs about the adquisition of Falithrom® for the German market | Download |
| 08 Jan 2019 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the fourth quarter of 2018 | Download |